Results 91 to 100 of about 64,379 (105)

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Blood, 2014
Guillaume Cartron, Marie-Sarah Dilhuydy
exaly  

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Molecular Cancer Therapeutics, 2013
Christian Klein, Sylvia Herter, Charles Dumontet   +2 more
exaly  

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial

Blood, 2015
Petra Langerbeins, Stephan Stilgenbauer, Anna Maria Fink   +2 more
exaly  

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

British Journal of Haematology, 2011
Christian Klein, Clemens Wendtner, Guenter Krause   +2 more
exaly  

Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Blood, 2009
Gilles Salles, Catherine Thieblemont, Guillaume Cartron   +2 more
exaly  

Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice.

Blood, 2008
Charles Dumontet, Lina Reslan
exaly  

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial Free

Blood, 2016
Matthias Ritgen, Stephan Stilgenbauer
exaly  

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies Free

Blood, 2011
Christian Klein, Karl-Peter Hopfner, Manfred Schwaiger   +2 more
exaly  

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Blood, 2012
Gilles Salles, Catherine Thieblemont, Guillaume Cartron   +2 more
exaly  

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption

Dermatology and Therapy, 2012
exaly